Search

everythinglearnresearchcommunity

for

Search:↓

Cyclosporine showed some improvement in alopecia areata but results were not statistically significant.

Some treatments for severe hair loss work but often have side effects, with baricitinib showing the most promise.

Baricitinib helps treat severe hair loss in people over 65.

Baricitinib helped most teenagers with severe hair loss regrow hair and had mild side effects.

The study's results on the effectiveness of low-dose IL-2 for alopecia areata and its impact on immune cells were not provided.

Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.

Tofacitinib is effective and has minor, reversible side effects for treating severe hair loss in Iran.

Tofacitinib may help treat severe hair loss, but more research is needed.

Apremilast was not effective in treating moderate-to-severe alopecia areata.

Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.

Tofacitinib improves nail conditions in patients with severe hair loss and does not affect hair regrowth.

Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.

Ruxolitinib effectively regrows hair in most patients with severe hair loss.

Tofacitinib is effective and safe for treating severe hair loss in Korean patients.

COVID-19 vaccines may rarely worsen hair loss in people with severe alopecia, but the benefits of vaccination still outweigh this risk.

Weekly azathioprine pulse is a better alternative to corticosteroids for treating alopecia areata due to fewer side effects.

Intralesional triamcinolone acetonide is more effective but has a higher relapse rate than platelet-rich plasma for treating alopecia areata.

Methotrexate with steroids is slightly more effective than azathioprine with steroids for treating severe alopecia areata.

Alopecia Areata significantly lowers quality of life and current treatments are inadequate, highlighting a need for better therapies and standardized treatment protocols.

Both treatments help with hair regrowth in alopecia areata, but azathioprine has milder side effects than betamethasone.

Tofacitinib helped regrow hair in most patients with severe hair loss.

Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.

JAK inhibitors show promise in treating moderate to severe alopecia areata.

JAK inhibitors are safe and effective for treating moderate-to-severe alopecia areata.

New treatments for severe alopecia areata, especially JAK inhibitors, are recommended as first-line therapy.

Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.

Intralesional corticosteroids work best for mild alopecia areata, and DPCP works best for moderate to severe cases.

Tofacitinib may help regrow hair in severe alopecia areata, but results differ greatly between people.

Higher levels of CCL7 are linked to more severe hair loss in alopecia areata patients.